In the rapidly evolving landscape of synthetic biology and microbiome research, Engineered Live Biotherapeutics (eLBPs), often referred to as "living medicines", represent a paradigm shift in therapeutic delivery. Unlike traditional probiotics, eLBPs are medicinal products consisting of live microorganisms (bacteria or yeast) genetically optimized to produce therapeutic molecules, sense disease biomarkers, or modulate the host immune system directly at the site of action.
As a premier Contract Research Organization (CRO), Creative Biolabs offers a high-performance, end-to-end eLBP Platform. We empower pharmaceutical companies and academic researchers to transition from "benchtop probiotics" to "clinical-grade live biotherapeutics" through rigorous engineering, comprehensive quality control, and scalable bioprocessing.
Overview: Architectural Excellence in Microbial Design
The human microbiome is no longer viewed merely as a community of passive bystanders; it is a dynamic ecosystem capable of being "programmed" to treat complex diseases. Engineered Live Biotherapeutics (eLBPs) represent a paradigm shift where synthetic biology meets microbiology.
By leveraging genetic engineering, we modify commensal bacteria or probiotics to sense specific disease biomarkers and respond by secreting therapeutic proteins, modulating host immune responses, or neutralizing toxins in situ. Our services bridge the gap between initial strain discovery and clinical readiness, offering a robust pipeline for the pharmaceutical, nutraceutical, and agricultural industries.
Service Portfolio
The construction of an eLBP is a multi-step process that requires balancing therapeutic efficacy with the biological fitness of the microbe. Our platform breaks this down into four critical pillars:
Chassis Strains
Design and Synthesis
Construction Types
QC
Deliverables
Selection of Chassis Strains
Choosing the right host is the foundation of any eLBP project. We offer a diverse library of well-characterized "chassis" strains, categorized by their ecological niche and regulatory history:
-
Conventional Probiotic Chassis: Including Escherichia coli Nissle 1917, Lactococcus lactis, and various Bifidobacterium or Lactobacillus species, known for their safety profiles and ease of manipulation.
-
Next-Generation Chassis: For specialized applications, we work with anaerobic commensals like Akkermansia municiphila and Bacteroides fragilis, which offer superior colonization in the gut.
-
Target-Specific Hosts: Selection based on the specific disease environment, ensuring the microbe can survive and thrive where the therapy is most needed.
Genetic Circuit Design and Synthesis
Using advanced in silico modeling, we design genetic circuits that can sense disease-specific biomarkers (e.g., specific metabolites, pH changes, or inflammatory cytokines).
-
Promoter Optimization: We utilize a library of constitutive and inducible promoters to fine-tune the timing and intensity of the therapeutic payload expression.
-
Codon Optimization: We ensure that the transgene is "translated fluently" by the host microbe, preventing metabolic bottlenecks.
Types of Genetic Construction
We employ a variety of engineering strategies tailored to the specific needs of your therapeutic molecule:
-
Genomic Integration: Using CRISPR-Cas or homologous recombination to insert therapeutic circuits directly into the chromosome, ensuring high stability without the need for antibiotic selection. Insertion of genes for the secretion of proteins, enzymes, or anti-inflammatory cytokines. This includes the optimization of secretion signals to ensure the payload reaches the target.
-
Plasmid-Based Expression: For high-copy number expression where maximum payload delivery is required, using stabilized, toxin-antitoxin or auxotrophy-based maintenance systems.
-
Surface Display & Secretion: Engineering specialized secretion tags (e.g., HlyA or signal peptides) to ensure the drug reaches the extracellular environment or the host cell surface effectively.
-
Gene Knockout (Loss-of-Function): Using CRISPR-Cas or homologous recombination to delete specific genes. This is often used to eliminate virulence factors, remove antibiotic resistance markers, or redirect metabolic flux toward a desired byproduct.
-
Fluorescent and Luminescent Tagging: Construction of "reporter strains" expressing markers like GFP, mCherry, or Luciferase. These are essential for tracking microbial localization, colonization density, and transit time in in vivo imaging studies.
Quality Control and Verification
Reliability is the cornerstone of our CRO services. Every engineered strain undergoes a strict validation protocol:
-
Sequencing Verification: We utilize Sanger Sequencing for targeted insert verification or Whole Genome Sequencing (WGS) to ensure the absence of off-target effects and confirm the genetic "identity" of the strain.
-
Expression Analysis: Confirmation of the target protein or metabolite production via Western Blot, ELISA, or LC-MS.
Deliverables
At the conclusion of each project, we deliver a comprehensive package designed for immediate use in your preclinical pipeline:
-
The Engineered Strain: Provided as a Master Cell Bank (MCB) in cryopreserved format, along with the parental strain. (1mL/vial, 2 vials/strain)
-
Comprehensive Project Report
Ready to start your construction project? To provide you with a precise technical scheme and a competitive quotation,
Please download and complete our:
Download: eLBP Technical Requirement & Project Specification Form (PDF)
Products
We offer a range of pre-engineered, standardized probiotic strains that serve as ready-to-use platforms for research:
Genetically Modified Probiotics (GMP)
-
Reporter-Labeled Probiotics: Strains of Lactobacillus reuteri or Bifidobacterium longum expressing fluorescent proteins (GFP, mCherry) or luciferase for real-time in vivo imaging and colonization tracking.
-
Metabolite-Secreting Benchmarks: Validated strains engineered to produce high levels of short-chain fatty acids (SCFAs) or specific antioxidants, serving as positive controls for your therapeutic assays.
-
Modular Expression Vectors: A library of plasmids with varying strengths of promoters and secretion signals, pre-optimized for specific probiotic chassis.
Mechanism of Action (MoA) of eLBPs
Unlike traditional LBPs that rely on the natural properties of a strain, eLBPs function through "Sense-and-Respond" logic:
-
Targeted Secretion: Bacteria are engineered to secrete therapeutic proteins (enzymes, cytokines) only in the presence of specific disease biomarkers (e.g., inflammatory markers, hypoxia, or specific metabolites).
-
Metabolic Rewiring: Modifying the bacterial metabolic pathways to consume toxic metabolites (e.g., ammonia in UCD or phenylalanine in PKU) or produce beneficial ones (e.g., SCFAs).
-
Surface Display: Engineering the bacterial cell wall to express ligands that bind to gut epithelium or tumor cells, enhancing colonization and localized delivery.
-
Biocontainment: Implementation of "Kill Switches" or auxotrophy to ensure the therapeutic agent does not persist in the environment or the host beyond the treatment window.
Our Competitive Advantages
Why partner with a specialized CRO for your eLBP journey?
Expertise in Anaerobic Engineering
Many eLBP candidates are strict anaerobes. We possess the specialized equipment and expertise to handle, engineer, and characterize these sensitive organisms without compromising their viability.
Scarless Modification Technology
Our methods leave no "genetic scars" or antibiotic resistance markers behind, a crucial factor for clinical safety and regulatory acceptance.
Integrated Pipeline
By combining strain construction with preclinical analysis, we eliminate the friction of transferring materials between different service providers. We provide a single point of accountability for your project.
The complexity of living medicines is matched only by their potential to cure previously untreatable conditions. However, the path to a successful eLBP is paved with technical challenges that require more than just standard analytical tools; it requires a deep, intuitive understanding of microbial life.
By integrating precision engineering with robust preclinical validation, we provide the clarity and confidence you need to advance your candidate. We don't just provide data; we provide a roadmap for the future of medicine. Whether you are a startup at the conceptual stage or a large pharmaceutical company refining a lead candidate, our team is ready to provide the specialized support your project deserves.
Would you like me to prepare a customized technical proposal for your specific chassis, or should we schedule a consultation to discuss the biocontainment strategies for your lead candidate?
Frequently Asked Questions (FAQs)
How do you determine the best site for chromosomal integration?
We use transcriptomic mapping to identify "transcriptionally active but non-essential" regions of the genome. This ensures that the insertion does not disrupt the microbe's core fitness while allowing for high expression of your therapeutic gene.
Can you engineer strains to respond to external triggers, like a specific food component?
Yes. We have experience building "diet-inducible" systems where the therapeutic payload is only produced when the patient consumes a specific, safe inducer, such as a particular sugar or fiber.
What is the typical timeline for a custom strain construction project?
Depending on the complexity of the genetic circuit and the chosen chassis, the process typically takes 6 to 10 weeks from initial design to the delivery of a validated Master Cell Bank (MCB).
